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In patients with cardiac sarcoidosis, ventricular tachycardia (VT) is observed in some cases.
However, eﬀective therapies for the VT are still unknown.
Case: A 50-year old female with cardiac sarcoidosis underwent DDD pacemaker
implantation for a high degree atrioventricular block with symptoms of faintness and
shortness of breath. One month after the surgery, she was admitted for frequent episodes of
non-sustained VT. In the electrophysiologic study (EPS), sustained monomorphic VT and
ventricular ﬁbrillation were induced; therefore pacemaker was replaced with implantable
cardioverter-deﬁbrillator (ICD). Amiodarone was started orally but it couldn’t suppress
frequent VT episodes, and frequent ICD shocks were delivered. When the oral steroid therapy
was initiated for the cardiac sarcoidosis, it not only suppressed the frequent VT but also
improved the atrioventricular nodal dysfunction.
In conclusion, steroid therapy might be an option to consider in cardiac sarcoidosis with
refractory VT.
(J Arrhythmia 2007; 23: 296–302)
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Introduction
In patients whose cardiac dysfunction was the
result of cardiac sarcoidosis, sudden death is the
most common cardiac manifestation.1) Ventricular
tachycardia (VT) and complete heart block are
among the causes, and are frequently observed.
For the treatment of VT associated with cardiac
sarcoidosis, the implantable cardioverter-deﬁbrilla-
tor (ICD) is necessary to prevent the arrhythmic
events.2–4) However the best way of bailing out the
frequent VT and ICD shocks has not been estab-
lished. In this article, we report a case with cardiac
sarcoidosis in which VT was suppressed and
atrioventricular nodal function was improved by
oral steroid therapy.
Case Report
A 50-year-old woman was hospitalized for symp-
toms of faintness and shortness of breath. She was
diagnosed as cardiac sarcoidosis 4 years ago from
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the left bundle branch block in electrocardiography
(ECG), diﬀuse left ventricular hypocontractility with
an ejection fraction (EF) of 26 percent in echocar-
diography, lung and liver nodules, and the accumu-
lation of Gallium-67 in the heart. Histologic diag-
nosis was not made because she did not consent to
the biopsy. A dose of oral prednisolone 60mg every
other day eﬀectively improved the ECG ﬁnding of
intraventricular conduction disorder and the accu-
mulation of Gallium-67 disappeared, but the left
ventricular contraction improved only slightly. Other
medications including digoxin, spironolactone and
carvedilol were also eﬀective and she had no acute
exacerbation of heart failure and sarcoidosis for 4
years. Dose of steroid was tapered to 2mg per day.
But this time of admission 12-lead ECG showed type
II second degree atrioventricular block, left anterior
hemiblock and non-speciﬁc ST-T change (Figure 1)
for the ﬁrst time for 4 years. A dual chamber
pacemaker was implanted.
One month after pacemaker implantation, chest
X ray revealed the enlargement of cardiac silhou-
ette with cardiothoracic ratio increasing from 46 to
50 percent and she was hospitalized and treated
with diuretics. During this hospitalization no
arrhythmia event was demonstrated, but episodes
of non-sustained VT (NSVT) were documented at
the pacemaker clinic. She had late potentials on the
signal averaged ECG (total QRS 184ms, HFLA
71ms, RMS40 12 mV) in sinus rhythm, and EF
was 18.7 percent in quantitative gated myocardial
single photon emission computed tomography.
There thought to be the arrhythmogenic scar in
the heart and electrophysiologic study was per-
formed to evaluate the inducibility of ventricular
arrhythmias.
Electrophysiologic Study
The electrophysiologic study was undertaken
while the patient was sedated. Sustained monomor-
phic VT (VT1) was reproducibly induced by
programmed stimuli at the right ventricular apex
(Figure 2a). VT1 changed to clinical VT (VT2) after
direct current shock with 300 J (Figure 2b), and
degenerated into ventricular ﬁbrillation with rapid
right ventricular outﬂow tract pacing. The morphol-
ogy of both VT1 and VT2 was left bundle branch
block with a superior axis, the cycle length of which
was 280ms and 360ms, respectively. Though de-
tailed mapping was not performed, estimated exit
sites of both VTs were the left ventricular mid–
septum or the right ventricular mid-region.5) The left
ventriculography showed diﬀuse severe hypokinesis
with EF of 7 percent and severe mitral regurgitation
but coronary angiography exhibited no signiﬁcant
coronary stenosis. Subsequently, an ICD was im-
planted for primary prevention of sudden cardiac
death and pacemaker and ventricular lead was taken
out.
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Figure 1 Surface twelve-lead ECG.
Surface twelve-lead ECG revealed type II second degree atrioventricular block, left anterior hemiblock and non-speciﬁc ST-T change.
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Clinical Course
After the implantation of ICD, the value of BNP
and cardiothoracic ratio got worse from 236 pg/ml to
370 pg/ml and 46 percent to 53 percent, respective-
ly, which was thought to be due to the frequent
PVCs, NSVT and dyssynchronized pacing. The
dosage of the diuretics was increased and the both
values got improved. Though the status of heart
failure got improved, the cardiac function in echo-
cardiography did not get better and the frequency of
NSVT (Figure 3), sustained VT (Figure 4) and ICD
shocks became increased. Oral amiodarone and beta
blockers failed to suppress them. The physical
ﬁndings and the laboratory data, including the value
of Ca, showed no abnormalities with the exception
of slight elevation of lysozyme and the serum protein
fractionation of  globulin (9.4 and 24.4 percent,
respectively). The level of ACE remained normal
range with the value of 13.5 IU/l, which was slightly
higher than her control level of about 5 IU/l. The 24
hours Holter ECG detected 3633 PVCs, 129 couplets
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a: Programmed electrical stimulation.
Monomorphic ventricular tachycardia
(VT1) was reproducibly induced at 3
extrastimuli from the site of the outﬂow
tract of the right ventricle. S1S1: basic
stimulation. S1S2: coupling interval of
ﬁrst extrastimulus. S2S3: coupling in-
terval between ﬁrst and second extra-
stimlus. S3S4: coupling interval be-
tween second and third extrastimulus.
HRA: high right atrium. RVOT: out-
ﬂow tract of the right ventricle.
b: VT1 changed into VT2. VT1
changed into VT2 which was clinically
demonstrated by direct current shock
with 300 joules. DC: direct current.
J: joule
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and 268 triplets or NSVTs of more than 10 beats. We
diagnosed that the cardiac sarcoidosis was active
based on the cardiac arrhythmia and abnormal
laboratory ﬁndings of lysozyme and the serum
protein fractionation of  globulin, and 60mg of
oral prednisolone every other day was started. After
the initiation of the steroids, the value of ACE
returned to her control level of 5.5 IU/l and the 24
hours Holter ECG detected 1261 PVCs without
NSVTs per day, which was remarkably fewer than
before. Moreover, ICD shocks were suppressed and
the NSVT were terminated spontaneously within
4 or 5 beats, and atrioventricular nodal function
improved as well (Figure 5). During the admission
period, echocardiographic evaluation was repeatedly
performed, but it was limited by the poor view.
Though detailed evaluation had been diﬃcult, left
ventricular diastolic diameter and EF remained about
62mm and 30 percent, respectively.
Discussion
In patients with cardiac sarcoidosis, the mecha-
nism of VT is thought to be reentry or abnormal
automaticity.4) Usually the steroid therapy halts the
progression of cardiac disease and improves surviv-
al, but it is not the enough treatment to control the
ventricular arrhythmias.3) Antiarrhythmic agents and
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Figure 3 24 hour Holter ECG.
24 hour Holter ECG revealed frequent NSVTs. Shown is the CC5 recording. NSVT occurred frequently during the daytime.
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beta blockers are often used together with steroid,
but these agents still can not control the arrhythmia
completely, even when guided with EPS. So it is
recommended to place the ICD for the ventricular
tachycardia.3,6) To evaluate the arrhythmic risk,
programmed ventricular stimulation is useful to
predict the future arrhythmic event.6) Aizer et al.
reported that 10 of 12 patients who underwent ICD
insertion received appropriate ICD shocks.
Although the mechanism of steroid treatment in
cardiac sarcoidosis is unknown, it is reported that
steroid therapy can cause healing of cardiac gran-
ulomas, which is a possible cause of the cardiac
aneurysms.1) Regarding the cardiac function, Chiu
CZ et al. reported that patients with an ejection
fraction of over 30 percent and under 55 percent
beneﬁted from steroid therapy.7)
In this patient, entrainment phenomenon was not
demonstrated because of the degeneration into VF by
rapid ventricular pacing, but programmed ventricular
stimulation reproducibly induced the VT. Though it
is diﬃcult to determine the mechanism of VT, ICD
was implanted, and it delivered the appropriate
shocks.
In this case there thought to be myocardial scars as
well as active sarcoid granulomas in the heart.
Reproducible inducibility of VT suggests that the
mechanism of VT may be reentry, but healing of
the granulomas by steroid therapy might eliminate
the focus of the automaticity. The frequency of VT
and PVCs increased after improvement of heart
failure, which suggests that the arrhythmic event was
caused by active cardiac sarcoidosis. After steroid
therapy, though no improvement or deterioration
of the EF and the left ventricular diameter was
revealed in echocardiography, VT was suppressed.
The frequency of PVCs was also remarkably
decreased. Based on these ﬁnding, the suppression
of VT might be caused by decreased PVCs by steroid
therapy, even though there may remain the in-
creased myocardial scars which cause ventricular
arrythmias.
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Figure 4 Surface twelve-lead ECG.
Surface twelve-lead ECG revealed VT with the
morphology of right bundle branch block and
superior axis and tachycardia cycle of 450ms.
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Roberts et al. reported that in the majority of
patients with cardiac sarcoidosis causing cardiac
dysfunction, there was no clinical evidence of the
dysfunctions of other organ systems other than the
heart.1) This time the systemic examination includ-
ing Gallium-67 scintigraphy could not reveal any
typical abnormality. Though in some cases the value
of ACE or Gallium-67 scintigraphy is useful to
detect the activity of the disease,8) these examina-
tions disclosed no abnormal ﬁndings in this patient.
The number of PVCs in Holter ECG and the value of
ACE, even if it remained the normal range, might be
useful to speculate the activity of sarcoidosis and
determine the doses of steroid in this case. And if the
activity of sarcoidosis is controlled, then tapering the
dose of prednisolone had better been attempted
gradually to 10–15mg per day over a period of 6
months.8)
In cardiac sarcoidosis, ICD implantation is rec-
ommended for the VT, and when VT and ICD
shocks occur frequently, it is necessary to evaluate
the disease activity. In the patients with active
sarcoidosis, there might be some cases which steroid
therapy is eﬀective to suppress the arrhythmic
events. In the case of VT without active sarcoidosis,
though the eﬃcacy is not established, catheter
ablation rather than higher doses of steroid might
be needed.
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